Aurora (TSX:ACB) Stock Just Slumped 26% Yesterday!

Aurora Cannabis (TSX:ACB) stock lost a quarter of its market value after the company disclosed intentions to raise US$125 million in equity capital.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Shares of pot giant Aurora Cannabis (TSX:ACB)(NYSE:ACB) fell over 26% on November 10 after it gained 176% in the previous six trading days. Aurora stock also fell 16.4% in after-hours trading on the NYSE yesterday.

Aurora Cannabis and peers gained momentum, as Joe Biden won the U.S. presidential race. During the pre-election debate, Vice-President-Elect Kamala Harris had emphasized the need to decriminalize marijuana at the federal level in the U.S., which sent pot stocks soaring after the Democrats won the election.

On November 9, Aurora Cannabis also disclosed its fiscal first quarter of 2021 results and reported net revenue of $67.8 million, indicating a 1% sequential gain and a fall of 10% year over year.

The company reported an adjusted EBITDA loss of $57.9 million, which includes restructuring costs of $47.4 million. After accounting for these charges, EBITDA loss stood at $10.5 million. Aurora claimed it is in compliance with its September 30th term debt covenants and is on the road to achieving a positive EBITDA in the December quarter.

Aurora Cannabis sales declined in Q1

Aurora stock gained 15% after its Q1 results, as it had forecast sales between $60 million and $64 million. While ACB beat its own guidance, its sales were up just marginally up on a sequential basis.

Aurora divested a few of its non-core businesses in the last few quarters, which contributed to its less-than-impressive revenue growth. However, its net cannabis sales fell 4% year over year in Q1, which means it is losing market share in a highly competitive but fast-growing space.

Aurora said its consumer cannabis net revenue totaled $34.3 million, which was 3% lower than sales in the prior-year period. This figure could have been lower, as Aurora confirmed consumer cannabis revenue was driven higher by $1.1 million due to its U.S. CBD sales after it acquired Reliva earlier this year.

Comparatively, Canopy Growth also reported its quarterly results, growing sales by 23% year over year to a record high of $135.3 million.

What’s next for ACB stock investors?

While Aurora expects to achieve a positive EBITDA in Q2, its operating loss stood at $107.2 million in the September quarter. The company is trying to grow the bottom line by slashing costs instead of top-line growth, which will make long-term investors nervous.

ACB also said it aims to achieve a positive free cash flow by the end of fiscal 2021, which will also mean it will not have to issue equity shares and dilute shareholder wealth. However, ACB stock lost a quarter of its market value yesterday after it announced another public offering.

Aurora said it will issue company units at a price of US$7.5 to raise US$125 million. Each unit will comprise one common share and one half of one common share purchase warrant. Further, each warrant will be exercisable to acquire one common share of ACB at an exercise price of US$9. Aurora stock closed trading at US$8.3 on November 10.

It’s clear that Aurora Cannabis will have to improve profit margins and cash flow in the near term, or the stock will experience another free fall from current prices and continue to burn investor wealth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »